Diazepam
Diazepam (Valium) is a long-acting benzodiazepine for anxiety, seizures, and muscle spasm; it causes dependence, is dangerous with opioids or alcohol, and withdrawal can be dangerous.
Overview
Diazepam, widely known by the brand name Valium, is a long-acting benzodiazepine used for anxiety, seizures, muscle spasm, and alcohol withdrawal. It is an effective, long-established medication, but like all benzodiazepines it carries a significant risk of tolerance and dependence with regular use, and it is dangerous when combined with other central-nervous-system depressants. Its long duration of action means it stays in the body for an extended time, which affects both how it is used medically and how dependence and withdrawal play out. It is also misused, and counterfeit benzodiazepine pills sold illicitly are a growing hazard.
Source: MedlinePlus; DEA; PubChem CID 3016
Chemistry & mechanism of action
Diazepam enhances the effect of GABA, the brain's main inhibitory neurotransmitter, by making GABA's calming signal more effective. This slows central nervous system activity, which reduces anxiety, relaxes muscles, suppresses seizures, and produces sedation. The same mechanism is why benzodiazepines are dangerous in overdose and especially in combination with other depressants: when CNS activity is suppressed too far, breathing slows. With repeated use the brain adapts to the drug's presence, producing tolerance and physical dependence, so the nervous system becomes over-excitable if the drug is suddenly removed — the basis of a withdrawal syndrome that can be medically dangerous. Diazepam's long half-life means it and its active breakdown products linger in the body.
Source: MedlinePlus; PubChem CID 3016
Effects
Diazepam reduces anxiety and produces sedation, muscle relaxation, and a sense of calm. Common effects include drowsiness, fatigue, poor coordination, slurred speech, and impaired memory and concentration; some people experience paradoxical agitation. It impairs driving and tasks needing alertness, and its long duration means effects and grogginess can persist into the next day. With repeated use, tolerance develops and dependence can form; stopping abruptly after regular use can cause rebound anxiety and insomnia and, in more serious cases, a dangerous withdrawal that includes seizures. Because it is long-acting, withdrawal tends to start later and last longer than with short-acting benzodiazepines.
Source: MedlinePlus
Risks & harms
Two dangers stand out. The first is combination with other depressants: taken with opioids, alcohol, or other sedatives, diazepam compounds the suppression of breathing and is a frequent factor in fatal overdoses — regulators carry explicit warnings about benzodiazepine-and-opioid combinations. The second is withdrawal: after regular use, stopping suddenly can trigger seizures and other dangerous symptoms, so discontinuation should be done gradually under medical supervision, never abruptly and alone. A third growing risk is the counterfeit market — pills sold illicitly as Valium or other benzodiazepines may contain different benzodiazepines, other drugs, or fentanyl in unpredictable amounts, so naloxone (over the counter in the U.S. since 2023) is worth having on hand because these pills can cause an opioid overdose. If you suspect an opioid overdose from a counterfeit pill, give naloxone and call 911. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: MedlinePlus; DEA; FDA; SAMHSA
Legal status (US)
In the United States, diazepam is a Schedule IV controlled substance under the Controlled Substances Act: it has an accepted medical use and a lower abuse potential than Schedule II or III drugs, but it still carries a recognized risk of abuse and dependence and is available only by prescription, with limits on refills. Possessing or selling it without a valid prescription is illegal, and counterfeit versions are illicit drugs regardless of how they are labeled. Internationally, diazepam is controlled under the United Nations Convention on Psychotropic Substances and is recognized by the World Health Organization as an essential medicine, so most countries permit its medical use while controlling it. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Convention on Psychotropic Substances (1971); WHO
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With depressants, the danger is over-sedation: if someone is very drowsy, hard to wake, or breathing slowly, treat it as an emergency.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 3016PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C16H13ClN2OPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- AAOVKJBEBIDNHE-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- valium, Valium, Ansiolisina, Diazemuls, Apaurin, Faustan, Relanium, Seduxen, Sibazon, Stesolid, BialzepamPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- HUMAN PRESCRIPTION DRUGopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Diazepam is a long-acting benzodiazepine that boosts the calming neurotransmitter GABA. Used for anxiety, muscle spasm, seizures and alcohol withdrawal, it produces sedation, muscle relaxation, eased anxiety and drowsiness. Its defining feature is pharmacokinetic: diazepam is converted into active metabolites that themselves persist for a long time, so both its effects and its presence in the body are notably prolonged.PubChem CID 3016 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Diazepam's long half-life and active metabolites mean it accumulates with repeated use and clears slowly, so sedation can build up over days. As with the whole class, its gravest danger is combination: taken with opioids or alcohol it can produce fatal respiratory depression — the co-depressant synergy behind many overdose deaths. It causes tolerance and dependence, and stopping abruptly after sustained use can bring a withdrawal syndrome that, distinct from opioid withdrawal, may include seizures and prove life-threatening, so it requires a slow, supervised taper. Everyday drowsiness and impaired coordination also raise the risk of accidents.PubChem CID 3016 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Diazepam's labelling leads with the benzodiazepine–opioid combination: used together they risk life-threatening sedation, slowed breathing, coma and death, so co-prescribing is limited to cases where no other option exists. Alcohol and other CNS depressants compound the effect. Because diazepam is broken down by liver enzymes (including CYP3A4 and CYP2C19), drugs that inhibit those enzymes can raise its levels and prolong its already-long action.DailyMed §7 / boxed warning ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 76different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 76 variants
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ASCLEMED USA INC.
- Schedule
- CIV
- NDC
- 76420-314 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- PD-Rx Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 43063-970 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ASCLEMED USA INC.
- Schedule
- CIV
- NDC
- 76420-315 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- ASCLEMED USA INC.
- Schedule
- CIV
- NDC
- 76420-316 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- PD-Rx Pharmaceuticals, Inc.
- Schedule
- CIV
- NDC
- 43063-987 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- N 38
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sunrise Pharmaceutical, Inc.
- Schedule
- CIV
- NDC
- 11534-199 ↗ · 2026-06-18
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Safecor Health, LLC
- Schedule
- CIV
- NDC
- 48433-027 ↗ · 2026-06-18
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- N 41
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sunrise Pharmaceutical, Inc.
- Schedule
- CIV
- NDC
- 11534-202 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Safecor Health, LLC
- Schedule
- CIV
- NDC
- 48433-028 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- N 38
- Color
- YELLOW
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sunrise Pharmaceutical, Inc.
- Schedule
- CIV
- NDC
- 11534-203 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Safecor Health, LLC
- Schedule
- CIV
- NDC
- 48433-029 ↗ · 2026-06-18
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Mylan Institutional Inc.
- Schedule
- CIV
- NDC
- 51079-284 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Mylan Institutional Inc.
- Schedule
- CIV
- NDC
- 51079-285 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Mylan Institutional Inc.
- Schedule
- CIV
- NDC
- 51079-286 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 71335-2306 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 63629-1523 ↗ · 2026-06-18
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- A-S Medication Solutions
- Schedule
- CIV
- NDC
- 50090-0195 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Cardinal Health 107, LLC
- Schedule
- CIV
- NDC
- 55154-5074 ↗ · 2026-06-18
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-783 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-784 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Clinical Solutions Wholesale, LLC
- Schedule
- CIV
- NDC
- 58118-4047 ↗ · 2026-06-18
- Strength
- DIAZEPAM 5 mg/1
- Imprint
- D 5
- Color
- YELLOW
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Aurobindo Pharma Limited
- Schedule
- CIV
- NDC
- 59651-653 ↗ · 2026-06-18
- Strength
- DIAZEPAM 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Advanced Rx Pharmacy of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0120 ↗ · 2026-06-18
- Strength
- DIAZEPAM 2 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Clinical Solutions Wholesale, LLC
- Schedule
- CIV
- NDC
- 58118-3925 ↗ · 2026-06-18
Dosage
Pending medical reviewer
